EUVIMEDEUVIMED entdecken
Open Access

Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease

Tanya M Laidlaw, Kathleen M Buchheit, Katherine N Cahill, Jonathan Hacker, Laura Cho, Jing Cui, Chunli Feng, Chongjia C Chen, Meghan Le, Elliot Israel, Joshua A Boyce

Journal of Allergy and Clinical Immunology · 2023

DOI: 10.1016/j.jaci.2023.03.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023. Verfasst von Tanya M Laidlaw und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass…. Hauptthemen laut MEDLINE: Asthma, Aspirin-Induced, Sinusitis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is the triad of asthma, nasal polyposis, and respiratory reactions to COX-1 inhibitors. Overproduction of cysteinyl leukotrienes and underproduction of prostaglandin E2 (PGE2) are hallmarks of AERD. A mouse model predicted a key role for the thromboxane-prostanoid (TP) receptor in AERD. OBJECTIVE: Our aim was to determine whether ifetroban, a TP receptor antagonist, attenuates aspirin-induced respiratory symptoms in patients with AERD. METHODS: A total of 35 patients with AERD completed a 4-week double-blinded, placebo-controlled trial of ifetroban and underwent an oral aspirin challenge. The primary outcome was change in the provocative dose of aspirin that caused a 2-point increase in Total Nasal Symptom Score. Changes in lung function, eicosanoid levels, and platelet and mast cell activation were assessed. Cultured human nasal fibroblasts were stimulated with or without the TP agonist U46619 and assayed for prostanoid production. RESULTS: Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = .763). Participants taking ifetroban had greater aspirin-induced nasal symptoms and a greater decline in FEV1 value than did participants receiving placebo (-18.8% ± 3.6% with ifetroban vs -8.4% ± 2.1% with placebo [P = .017]). Four weeks of ifetroban significantly increased urinary leukotriene E4 levels and decreased nasal PGE2 levels compared with placebo. Peak aspirin-induced urinary thromboxane levels correlated with peak urinary leukotriene E4 and prostaglandin D2 metabolite levels in participants taking ifetroban. U46119 significantly potentiated the production of PGE2 by cultured nasal fibroblasts from subjects with AERD but not by cultured nasal fibroblasts from controls without polypoid sinusitis. CONCLUSION: Contrary to our hypothesis, TP receptor blockade worsened aspirin-induced reactions in AERD, possibly by exacerbating dysregulation of the eicosanoid system. TP signaling on stromal cells may be critical to maintaining PGE2 production when COX-2 function is low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Asthma, Aspirin-InducedSinusitisAnimalsMiceHumansProstaglandinsThromboxanesLeukotriene E4Receptors, ThromboxaneAspirinEicosanoidsDinoprostoneHomeostasisOxazolesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

AERDAspirin-exacerbated respiratory diseaseSamter triadifetrobanmast cellplateletthromboxane receptor

Substanzen

ProstaglandinsThromboxanesLeukotriene E4Receptors, ThromboxaneAspirinEicosanoidsDinoprostoneifetrobanOxazolesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Medicine, Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass. Electronic address: tlaidlaw@bwh.harvard.edu.
  • Department of Medicine, Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
  • Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
  • Department of Medicine, Harvard Medical School, Boston, Mass; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Mass.
  • Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, Mass.

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Laidlaw, T. M., Buchheit, K. M., Cahill, K. N., Hacker, J., Cho, L., Cui, J., Feng, C., Chen, C. C., Le, M., Israel, E., & Boyce, J. A. (2023). Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.03.030

Vancouver

Laidlaw TM, Buchheit KM, Cahill KN, Hacker J, Cho L, Cui J, et al. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.03.030

BibTeX
@article{Laidlaw2023,
  author = {Laidlaw, Tanya M and Buchheit, Kathleen M and Cahill, Katherine N and Hacker, Jonathan and Cho, Laura and Cui, Jing and Feng, Chunli and Chen, Chongjia C and Le, Meghan and Israel, Elliot and Boyce, Joshua A},
  title = {Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  doi = {10.1016/j.jaci.2023.03.030}
}
Kostenlos starten →